SYNOPSIS OF KEY GYNECOLOGIC ONCOLOGY THIALS

Synopsis of Key Gynecologic Oncology Trials 

Gynecologic oncology is a rapidly evolving field in women’s cancer care, driven by large clinical trials that inform prevention methods, diagnostic strategies, surgical approaches, systemic therapies, and survivorship outcomes. Understanding pivotal trials helps clinicians apply evidence-based practice and optimize patient outcomes across cervical, ovarian, endometrial, vulvar, and vaginal cancers.

1. Cervical Cancer: Prevention & Screening Trials

a. HPV Vaccine Trials (e.g., FUTURE, PATRICIA, Costa Rica Vaccine Trial)

Human papillomavirus (HPV) is etiologically linked to almost all cervical cancers. Vaccine trials such as FUTURE I/II (quadrivalent vaccine) and PATRICIA (bivalent vaccine) demonstrated high efficacy in preventing high-grade cervical intraepithelial neoplasia (CIN 2/3) — a precursor to invasive cancer. These trials showed:

• >90% reduction in HPV-related CIN 2/3 in vaccine recipients

• Long-term protection with sustained antibody levels

• Effectiveness in HPV-naïve populations

These data underpin global recommendations for HPV immunization programs, which have dramatically reduced precancerous lesions and incidence in vaccinated cohorts.

b. Screening Modality Trials (e.g., HPV Testing vs. Cytology)

Large comparative studies have established HPV testing as superior to cytology (Pap smear) for primary cervical cancer screening. Trials such as ATHENA and SHIELD showed that HPV testing:

• Has greater sensitivity for high-grade lesions

• Detects disease earlier than cytology

• Allows longer screening intervals (5 years vs. 3 years)

These findings have reshaped screening guidelines worldwide, with many countries adopting HPV testing as the primary modality.

2. Ovarian Cancer: Debulking & Chemotherapy Trials

a. GOG-111 & GOG-158 — Platinum and Taxane Regimens

In epithelial ovarian cancer, combination chemotherapy has been a mainstay. The GOG-111 and GOG-158 trials compared cyclophosphamide–cisplatin versus paclitaxel–platinum regimens. Results demonstrated that:

• Paclitaxel plus cisplatin improved overall survival

• Taxane–platinum became the standard first-line chemotherapy backbone

This trial series cemented the role of taxanes in ovarian cancer therapy.

b. ICON3 & AGO-OVAR 3

Further studies explored alternative regimens and dosing schedules. ICON3 confirmed that paclitaxel plus carboplatin is as effective as paclitaxel–cisplatin with less toxicity, establishing carboplatin as the preferred platinum agent in combination therapy.

c. GOG-218 & ICON7 — Bevacizumab in Frontline Therapy

These trials evaluated the addition of bevacizumab (anti-VEGF) to standard chemotherapy and as maintenance:

• Demonstrated improved progression-free survival (PFS)

• Subgroup analyses suggested greater benefits in high-risk patients

While overall survival benefits were modest, bevacizumab has been incorporated into standard care for selected patients.

d. PARP Inhibitor Trials (SOLO-1, PRIMA, PAOLA-1)

Poly (ADP-ribose) polymerase (PARP) inhibitors have transformed maintenance therapy for ovarian cancer:

• SOLO-1: In BRCA-mutated patients, maintenance olaparib significantly increased PFS

• PRIMA: Niraparib improved PFS regardless of homologous recombination deficiency status

• PAOLA-1: Olaparib plus bevacizumab showed enhanced benefit

These landmark trials have established PARP inhibitors as standard maintenance therapy post-chemotherapy.

3. Endometrial Cancer: Risk Stratification & Adjuvant Trials

a. PORTEC (1 & 2)

The PORTEC trials evaluated the role of adjuvant radiotherapy in early endometrial cancer:

• PORTEC-1: Showed pelvic radiotherapy reduced locoregional recurrence but did not improve overall survival

• PORTEC-2: Compared brachytherapy with external beam radiotherapy, finding similar control with less morbidity in brachytherapy

These results shaped current practice towards selective use of radiotherapy.

b. GOG-258 & GOG-249

More recent trials examined chemotherapy and combined modalities:

• GOG-258 compared chemoradiation vs. chemotherapy alone in high-risk patients

• GOG-249 evaluated surgical staging and brachytherapy vs. external beam radiotherapy

Outcomes help clinicians tailor adjuvant therapy based on individual risk.

4. Vulvar & Vaginal Cancers: Sentinel Node Trials

a. GROINSS-V & GOG-173

These prospective studies assessed sentinel lymph node (SLN) biopsy in early vulvar cancer:

• Demonstrated low groin recurrence in carefully selected patients

• Reduced morbidity compared to full inguinofemoral lymphadenectomy

SLN biopsy is now recommended in selected early vulvar cancers, minimizing surgical complications.

5. Targeted Therapy & Immunotherapy Trials

a. Pembrolizumab (KEYNOTE Trials)

Immunotherapy has expanded into gynecologic cancers:

• KEYNOTE-158 & -028: Pembrolizumab showed durable responses in PD-L1-positive cervical cancers

• Pembrolizumab has been approved for recurrent/metastatic cervical cancer after platinum failure

These studies opened the door for immune checkpoint blockade in gynecologic oncology.

b. Anti-PD-1/PD-L1 in Ovarian and Endometrial Cancer

Trials assessing immunotherapy in other gynecologic malignancies continue to refine patient selection and combination strategies, especially in microsatellite instability–high or mismatch-repair–deficient tumors.

6. Surgical Trials: Minimally Invasive vs. Open Approaches

a. LACC Trial (Cervical Cancer)

The LACC (Laparoscopic Approach to Cervical Cancer) trial focused on early-stage cervical cancer surgery:

• Found higher recurrence and lower survival with minimally invasive radical hysterectomy vs. open surgery

• Prompted re-evaluation of surgical approaches worldwide

This trial underscored that minimally invasive techniques are not universally superior and highlighted the need for evidence before widespread adoption.

Conclusion

Key gynecologic oncology trials have systematically refined prevention, screening, surgical techniques, and systemic therapies. HPV vaccine and screening trials have transformed cervical cancer control. Ovarian cancer trials have introduced taxane chemotherapy, anti-angiogenesis agents, and PARP inhibitors. Endometrial cancer trials guide the use of radiotherapy and chemotherapy. Sentinel node studies improve surgical outcomes in vulvar cancer. Immunotherapy is expanding treatment horizons across tumor types. Understanding these trials enables clinicians to adopt evidence-based practice, tailor therapies to individual patient risk profiles, and improve survival and quality of life for women with gynecologic cancers.